Gainesville, FL – November 5, 2025 — Immunogenik, Inc., a biotechnology company pioneering next-generation immunotherapies for aggressive cancers, today announced a strategic partnership with HITLAB (Health Innovation Technology Lab) to accelerate the company’s U.S. clinical, regulatory, and investor readiness. The collaboration is designed to advance Immunogenik’s path to market expansion and Series A financing, leveraging HITLAB’s expertise in digital health, evidence generation, and strategic innovation to complement Immunogenik’s leadership in translational cancer immunotherapy.
“Our mission has always been to bring transformative therapies to patients with the most devastating cancers,” said Jianping Huang, MD, PhD, Founder and CEO of Immunogenik, Inc. “Partnering with HITLAB enables us to strengthen the operational and regulatory foundation that supports our clinical programs and to communicate our scientific impact effectively to investors and stakeholders.”
Immunogenik is advancing a diversified pipeline of proprietary therapeutic platforms, including:
Together, these programs form the foundation of Immunogenik's mission to overcome therapeutic resistance in solid tumors and expand the frontiers of cancer immunotherapy.
The partnership integrates cutting-edge science with strategic evidence-building, accelerating Immunogenik’s path from discovery to regulatory readiness, investor engagement, and patient impact. Under the alliance, “Immunogenik’s science represents the kind of breakthrough innovation that has the potential to redefine cancer treatment,” said Stan Kachnowski, PhD, MPA, Chair of HITLAB. “Our collaboration focuses on providing the strategic infrastructure and evidence generation needed to accelerate their path from discovery to clinical success.”
Immunogenik, Inc. is a biotechnology company pioneering innovative immunotherapies to treat aggressive cancers, including GBM, pediatric high-grade glioma, lung cancer brain metastasis (LBM), and other cancer types. By combining translational research, biotechnology innovation, and clinical strategy, Immunogenik is developing a robust pipeline of first-in-class cancer therapeutics with broad therapeutic potential. The company is preparing for a Series A fundraising round to support clinical development, regulatory milestones, and operational expansion in the U.S. market. Learn more at www.immunogenik.com.
HITLAB (Health Innovation Technology Lab) is a globally recognized innovation and evidence-generation organization dedicated to improving healthcare delivery through technology and data. Founded in 1998, HITLAB collaborates with startups, health systems, and Fortune 500 companies to validate and accelerate digital and life-science solutions that make healthcare more equitable, efficient, and human-centered. Learn more at www.hitlab.org. Please review HITLAB's press release regarding the partnership (HITLAB Partners with Immunogenik, Inc. to Accelerate Next-Generation Cancer Therapeutics and U.S. Market Expansion | HITLAB).
Press Office
Immunogenik, Inc.
📧 press@immunogenik.com
🌐 www.immunogenik.com/news